@alphavestcap $nwbo
Margin Buu
Re: CaptainObvious post# 850039
Monday, November 16, 2026 10:48:27 AM
Post# of 850071
these claims are unsubstantiated and appear to be false or heavily fabricated.
No peer-reviewed studies, clinical trial results, or reputable medical sources match the specific numbers or outcomes described (340 stage-4 glioblastoma patients, 296 complete eliminations within 6 weeks, 96% 5-year survival, $87,000 cost, routine abandonment of chemotherapy, etc.). Searches of scientific literature turn up nothing supporting those figures. The text matches a recent social media post rather than published research.
What the actual science shows
Photodynamic therapy (PDT) and related laser approaches (including laser interstitial thermal therapy, or LITT) for glioblastoma are real areas of research. Photosensitizers or nanoparticles can accumulate preferentially in tumor cells and be activated by light (including wavelengths near 690 nm in some nanoparticle work), often delivered via fiber optics or interstitial probes. This can generate reactive oxygen species or localized heat to damage cancer cells with relative selectivity.
However, the clinical results are far more modest:
• Small trials (typically tens of patients, not hundreds) report median overall survival in the range of roughly 20–28 months in selected cases—better than historical medians around 14–16 months for standard care in some cohorts, but not cures.
• One small pilot (INDYGO trial, ~10 patients) reported about 40% alive at 5 years with intraoperative PDT plus standard treatment; other series show lower long-term rates. Five-year survival for glioblastoma overall remains low (typically under 10%, often cited around 5%).
• Complete radiographic elimination in large numbers of stage-4 patients with zero surrounding tissue damage is not reported. Recurrence is common, and these therapies are adjuncts or options for selected (often smaller or unresectable) tumors, not replacements for the Stupp protocol (surgery + radiation + temozolomide).
• Nanoparticle versions are mostly preclinical (cell and mouse studies) or very early-phase. Light penetration, blood-brain barrier, hypoxia, and tumor heterogeneity remain major challenges.
Claims about “quantum biology,” routine vaporization of inoperable tumors, rapid return to normal cognition in weeks across hundreds of patients, and chemotherapy being abandoned do not align with the evidence.
In short, light-activated therapies (PDT/LITT and related nanomedicine approaches) are legitimate research directions with some promising early signals in selected patients, but the dramatic “miracle cure” statistics in the post are unsupported.
2)
See new posts
Conversation
alphavestcapital.com@alphavestcap@t͏n͏o͏p͏s͏e͏d͏o͏r͏S͏u͏0͏1͏5͏1͏a͏m͏8͏m͏6͏1͏c͏h͏c͏h͏1͏c͏g͏0͏a͏1͏l͏f͏t͏f͏g͏l͏2͏h͏1͏t͏4͏7͏g͏0͏4͏a͏1͏9͏l͏a͏c͏i͏4͏0͏u͏u͏m͏8͏1͏ · A cancer miracle is unfolding in oncological photomedicine centers where inoperable tumors are being vaporized. Scientists inject photosensitive nanoparticles that accumulate in cancer cells, then activate them with 690nm laser light delivered through fiber optics. Out of 340 stage-4 glioblastoma patients treated, 296 showed complete tumor elimination within 6 weeks verified by MRI, with zero damage to surrounding brain tissue. The procedure costs $87,000 and requires one 4-hour surgery. Survival rates jumped from 14 months to 96% alive at 5 years. Chemotherapy is being abandoned. Patients return to normal cognition within weeks. Brain cancer is transforming from death sentence to curable disease through quantum biology. #BrainCancerCure #Phototherapy #GlioblastomaTreatment #NanoMedicine #OncologyBreakthrough See less@alphavestcap Views9:28 AM · Nov 16, 2026·39
$NWBO
The combo trial on rGBM doesn't include CSF1R blockade, the one that can deplete from tumor site the green dots which are immunosuppressive tumor-associated macrophages. Brain is the hardest location for activated t-cells to reach. Think of what would happen for other advanced solid tumors once DCVax-L + Hiltonol + Keytruda + CSF1R blockade was adopted to treat all those advanced solid tumors.
What could possibly bring Dr. Annalisa Jenkins to $NWBO? The absolutely revolutionary science!
$NWBO
AstraZeneca, Summit, and Daiichi Sankyo surely understand that a PD-1/VEGF bispecific can release the brakes on T cells (red dots) and help them infiltrate the tumor, and that a CSF1R inhibitor can deplete tumor-associated macrophages (green dots). Merck and Moderna surely understand this too.
They all know that getting t-cells into tumor site is the hardest part, don't they?
scotty3371 @alphavestcap
Monday, November 16, 2026 9:18:33 AM
Linda Liau' data clearly shows how efficacious dcvax-l is followed by pembro; but mhra is under orders from the bp cartel to string nwbo along till bankruptcy.
Fyi the soc for recurrent gbm is about 6.5 months. I guess getting about 18 patients to about 19 months mos is meaningless.
Mhra is where non toxic, zero side effect, vaccines goto die.
$nwbo @alphavestcap
VMLG17
Re: pgsd post# 850031
Monday, November 16, 2026 9:38:26 AM
Assuming she will be in attendance, here are some insights from Chat:
My assessment is that Dr. Annalisa Jenkins will most likely be speaking in her capacity as a broader life-sciences industry leader, rather than as an NWBO representative. However, her strategic-adviser relationship with NWBO makes her perspective particularly interesting to NWBO shareholders.
There is an important distinction between the capacity in which she is officially introduced and the professional experience she may bring to the discussion.
I checked the April 30, 2026 NWBO announcement, which confirms that she was appointed Strategic Adviser to Northwest Biotherapeutics. Her stated responsibilities include supporting the development and expansion of its dendritic-cell cancer vaccine platform. PR Newswire
1. What does the official conference programme tell us?
I examined the actual DIA–MHRA programme, including pages 13–14.
It identifies her as:
* Founder and Chair, The Conscience Collective
* Non-Executive Director, Genomics England
It does not identify her as an NWBO Strategic Adviser. DIA Global +2
This is significant because the conference is presenting her as an independent life-sciences industry voice, rather than explicitly as a representative of a particular biotechnology company.
2. Why her NWBO relationship is nevertheless interesting
Consider the subject of her keynote:
Investment signals.
She will be addressing the investment environment for life-sciences companies, including:
* What attracts institutional and private investment.
* How regulatory policy influences investment decisions.
* How investors assess innovative technologies.
* How companies move from scientific development toward commercialization.
* The importance of regulatory approval and patient access.
These subjects are directly relevant to NWBO and its DCVax platform.
Her previous experience is particularly relevant. She has led pharmaceutical R&D organizations, served as CEO of Dimension Therapeutics, and has extensive experience with biotech financing and commercialization. PR Newswire +1
3. Could she discuss NWBO indirectly?
Absolutely. In fact, I think this is where shareholders should pay attention.
She could discuss:
* The investment attractiveness of personalized cancer immunotherapies.
* The difficulties innovative cancer treatments face in obtaining regulatory approval.
* The importance of MHRA regulatory pathways.
* The challenges of financing late-stage biotechnology companies.
* How institutional investors evaluate companies with potentially transformative cancer technologies.
All of those topics could be relevant to NWBO without her ever mentioning the company.
However, we should not assume that her remarks will signal an imminent MHRA decision or an investment announcement involving NWBO.
4. My interpretation for NWBO shareholders
There are three distinct capacities worth separating:
Capacity Likely relevance
The Conscience Collective Her broader life-sciences leadership and innovation perspective
Genomics England NED Governance, genomics, health data and healthcare innovation
NWBO Strategic Adviser Direct experience with DCVax development and commercialization
The first two are her officially advertised conference affiliations. The third is a confirmed corporate appointment that the conference programme does not mention.
My conclusion: I would regard her participation as potentially meaningful for NWBO, but not as evidence that the summit is an NWBO-related event.
One additional detail deserves attention: she is not merely giving a keynote. She is also listed as a panelist in the subsequent 55-minute fireside discussion, alongside investment and biotechnology leaders, including Chris Bischoff of General Catalyst and Professor Chris Molloy of the BioIndustry Association. DIA Global
That extended discussion could be more revealing than her prepared keynote.
What I would watch particularly closely: Whether she discusses the willingness of investors to finance innovative therapies for diseases with substantial unmet medical needs, and whether she emphasizes regulatory approval as the catalyst for unlocking biotechnology investment.
Those would be highly relevant themes for NWBO, especially while its DCVax-L marketing authorization application remains under MHRA review.
$nwbo @alphavestcap
DIA 7moFollowWe are proud to announce the DIA–MHRA Global Summit: Global Collaboration for Safer and Smarter Health Innovation.
📅 November 16–17, 2026 | 📍 University of London, UK
Two organizations. One shared mission. DIA — the global life sciences community's trusted neutral convener for over 60 years. Medicines and Healthcare products Regulatory Agency — one of the world's most forward-thinking healthcare regulators. Together, united around one urgent goal: faster, safer patient access to breakthrough technologies.
This summit is where the conversations happen on the topics that matter most right now:
→ AI-driven drug discovery
→ Advanced therapies & cell & gene therapy
→ Real-world evidence & digital diagnostics
→ Clinical trials, preventative medicines & rare diseases
The frameworks being built around these technologies will shape global life sciences for the next decade. If you're not in the room, you're reading about it after the fact.
Why global leaders are coming to London:
💡 Regulatory Intelligence — direct access to MHRA leadership on AI, devices, diagnostics & digital health, immediately actionable for your global regulatory strategy
📊 World-Class Data — unparalleled access to the UK's NHS data infrastructure and RWE ecosystem, one of the most advanced real-world evidence environments in the world
🤝 Partnership Opportunities — licensing, investment, and collaboration with the UK's most exciting emerging biotechs, from Cambridge and Oxford to London
🌍 Shape Global Standards — bring your international perspective into a founding dialogue that will influence regulatory frameworks and industry standards well beyond the UK
Your voice isn't just welcome here — it's what makes this summit truly global.
→ Join the Founding Attendee Interest List: https://t.co/d02agYG00a
@alphavestcap
@t͏n͏o͏p͏s͏e͏d͏o͏r͏S͏u͏0͏1͏5͏1͏a͏m͏8͏m͏6͏1͏c͏h͏c͏h͏1͏c͏g͏0͏a͏1͏l͏f͏t͏f͏g͏l͏2͏h͏1͏t͏4͏7͏g͏0͏4͏a͏1͏9͏l͏a͏c͏i͏4͏0͏u͏u͏m͏8͏1͏ ·
A cancer miracle is unfolding in oncological photomedicine centers where inoperable tumors are being vaporized. Scientists inject photosensitive nanoparticles that accumulate in cancer cells, then activate them with 690nm laser light delivered through fiber optics. Out of 340 stage-4 glioblastoma patients treated, 296 showed complete tumor elimination within 6 weeks verified by MRI, with zero damage to surrounding brain tissue.
The procedure costs $87,000 and requires one 4-hour surgery. Survival rates jumped from 14 months to 96% alive at 5 years. Chemotherapy is being abandoned. Patients return to normal cognition within weeks. Brain cancer is transforming from death sentence to curable disease through quantum biology.
#BrainCancerCure #Phototherapy #GlioblastomaTreatment #NanoMedicine #OncologyBreakthrough See less
$nwbo @alphavestcap@ATLnsider@SchlangDaddy@glen_bwrhr42@smith348572
Poised for so much. With MAA approval, the market cap moves from $300 million to $20 billion over the next 6 months.
@RayEnriquez2103@peter_brit
"$NWBO will be represented by Dr. Annalisa Jenkins, who is scheduled to deliver keynote remarks on Tue, Nov 17, 3:15–4:30 PM. She will be introduced by MHRA's CEO Lawrence Tallon. Dr Jenkins is NWBO's strategic adviser."
https://t.co/zctkcQ2OLo
https://t.co/YwbRfO1CMC
https://t.co/kK1AlsELjj
https://t.co/AsqkVEYX7t
https://t.co/P3fYir6OyL (THE BIG SURPRIZE IN (https://t.co/cM3BnsPgT2) THE SEPTEMBER Q.)
https://t.co/6NUT9A5Fen
$nwbo @alphavestcap@SchlangDaddy@ATLnsider@glen_bwrhr42@smith348572
THE BIG SURPRIZE IN (https://t.co/zctkcQ2OLo) THE SEPTEMBER Q.
In the September q, we learned that technology from (? = It appears something got in-licensed from Harvard Deaconess-Avigan (https://t.co/ATz3DNwgi1) in the 9/30/26 quarter, which enables the first company sponsored trial to get teed up.Big company partner to put up the capital to pay for the trial? This will be the first Company-sponsored trial across its in-licensed portfolio which is now confirmed to include Roswell Park, Pittsburgh, and a Harvard-affiliated hospital." What is the technology LP wanted in-licensed from (https://t.co/ATz3DNwgi1) to $nwbo to add to the $nwbo combo components armamentarium ? https://t.co/0mLZC2prTf "II. Taking Direct Control of Clinical Trials + Harvard-Affiliated License To bypass slow academic grant cycles and university personnel shifts, NWBO built and trained its own internal clinical operations team, completed SOPs and regulatory filings, and officially selected the target indication for its first Company-sponsored trial across its in-licensed portfolio which is now confirmed to include Roswell Park, Pittsburgh, and a Harvard-affiliated hospital."
$NWBO@alphavestcap@SchlangDaddy@glen_bwrhr42@ATLnsider
"II. Taking Direct Control of Clinical Trials + Harvard-Affiliated License To bypass slow academic grant cycles and university personnel shifts, NWBO built and trained its own internal clinical operations team, completed SOPs and regulatory filings, and https://t.co/qF1TC8k1RM…
https://t.co/ydEJh3TfBf
https://t.co/6NUT9A5Fen
https://t.co/KZI5T7WAgo
1)Re: pgsd post# 850034 $nwbo @alphavestcap
Monday, November 16, 2026 6:49:19 AM
One interesting connection: NWBO's strategic adviser, Dr. Annalisa Jenkins, is scheduled to deliver keynote remarks at the DIA/MHRA Global Summit tomorrow.
She's listed on pages 13–14 of the official conference program.
2)pgsd
Re: None
Monday, November 16, 2026 4:08:07 AM
Post# of 850036
As well as the fact that Annalisa Jenkins presents at the end of this conference, The conference specifically state "the topics that matter most right now"
These topics just happen to be hugely relevant to DCVax, tells a story!
This summit is where the conversations happen on the topics that matter most right now:
AI-driven drug discovery
Advanced therapies & cell & gene therapy
Real-world evidence & digital diagnostics
Clinical trials, preventative medicines & rare diseases
The frameworks being built around these technologies will shape global life sciences for the next decade. If you're not in the room, you're reading about it after the fact.
Are MHRA going to release the final guidance on RWE/RWD at this conference ?
Why global leaders are coming to London:
💡 Regulatory Intelligence — direct access to MHRA leadership on AI, devices, diagnostics & digital health, immediately actionable for your global regulatory strategy
📊 World-Class Data — unparalleled access to the UK's NHS data infrastructure and RWE ecosystem, one of the most advanced real-world evidence environments in the world
🤝 Partnership Opportunities — licensing, investment, and collaboration with the UK's most exciting emerging biotechs, from Cambridge and Oxford to London
🌍 Shape Global Standards — bring your international perspective into a founding dialogue that will influence regulatory frameworks and industry standards well beyond the UK
https://t.co/X7xLrZzOnA
https://t.co/7PC54n1LO4
https://t.co/3ReJQgEgJB
https://t.co/xWCv0Aqbgq